RenovoRx, Inc., a life sciences company specializing in targeted oncology therapies, has announced the launch of the PanTheR Post-Marketing Registry Study. This multi-center, observational study aims to evaluate the long-term safety and survival outcomes of patients with solid tumors treated using the RenovoCath device for targeted drug delivery. The study will collect real-world data across diverse cancer types and clinical environments, providing insights into the device's safety and effectiveness in a real-world setting. Patient enrollment is expected to commence before the end of September 2025. The study's results have not yet been presented and will provide valuable data to inform future clinical trial designs and treatment strategies. Each participating cancer center will purchase RenovoCath devices for use in the study from RenovoRx.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.